CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A Comprehensive ddPCR Strategy for Sensitive and Reliable Monitoring of CAR-T Cell Kinetics in Clinical Applications.
A Comprehensive ddPCR Strategy for Sensitive and Reliable Monitoring of CAR-T Cell Kinetics in Clinical Applications.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在本研究中,我们介绍了数字微滴 PCR(ddPCR)的设计、实施及成功应用,用于监测在本临床中心接受不同 CAR-T 产品治疗的 B 细胞恶性肿瘤患者的CAR-T 细胞扩增。首先,我们设计了一种针对 tisa-cel 的 4-1BB 与 CD3 结构域之间连接区的特异性、高灵敏度 ddPCR 检测方法,以 RPP30 进行归一化,并使用瑞士首例接受 tisa-cel 治疗患者的血液样本进行了验证。
我们进一步将该检测方法与已发表的 qPCR(实时荧光定量 PCR)设计进行了比较。两种方法均能可靠定量低至 20 copies/ g DNA 的 CAR-T 拷贝数。通过大量测试和实验室间比对,证实了其可重复性和精密度。随着其他 CAR-T 产品的引入,我们还开发了针对 axi-cel 和 brexu-cel 的相应 ddPCR 检测方法,显示出高特异性和高灵敏度,检测下限为 20 copies/ g DNA。这些检测方法适用于多种样本类型(包括外周血、骨髓和淋巴结活检组织)的 CAR-T 拷贝数定量,表现稳健,并表明 CAR-T 细胞不仅存在于血液中,也存在于靶组织中。对 141 例接受 tisa-cel、axi-cel 或 brexu-cel 治疗患者的 CAR-T 细胞动力学纵向监测显示,CAR-T 细胞存在显著扩增和长期持续存在。扩增峰值与临床结局和不良反应相关,这一点目前已广为人知。
此外,我们对 CAR-T mRNA 表达进行了定量,结果显示其与 DNA 拷贝数高度相关,证实了转基因的活跃表达。我们的结果突显了ddPCR在CAR-T 监测中的质量,提供了一种敏感、精确且可重复的方法,适用于临床应用。这种方法可适用于未来的CAR-T 产品,并将支持CAR-T 细胞疗法的监测和管理。
In this study, we present the design, implementation, and successful use of digital droplet PCR (ddPCR) for the monitoring of chimeric antigen receptor T-cell (CAR-T) expansion in patients with B-cell malignancies treated with different CAR-T products at our clinical center. Initially, we designed a specific and highly sensitive ddPCR assay targeting the junction between the 4-1BB and CD3 domains of tisa-cel, normalized with RPP30 , and validated it using blood samples from the first tisa-cel-treated patient in Switzerland.
We further compared this assay with a published qPCR (quantitative real-time PCR) design. Both assays showed reliable quantification of CAR-T copies down to 20 copies/ g DNA. The reproducibility and precision were confirmed through extensive testing and inter-laboratory comparisons. With the introduction of other CAR-T products, we also developed a corresponding ddPCR assay targeting axi-cel and brexu-cel, demonstrating high specificity and sensitivity with a limit of detection of 20 copies/ g DNA.
These assays are suitable for CAR-T copy number quantification across multiple sample types, including peripheral blood, bone marrow, and lymph node biopsy material, showing robust performance and indicating the presence of CAR-T cells not only in the blood but also in target tissues. Longitudinal monitoring of CAR-T cell kinetics in 141 patients treated with tisa-cel, axi-cel, or brexu-cel revealed significant expansion and long-term persistence. Peak expansion correlated with clinical outcomes and adverse effects, as is now well known.
Additionally, we quantified the CAR-T mRNA expression, showing a high correlation with DNA copy numbers and confirming active transgene expression.
Our results highlight the quality of ddPCR for CAR-T monitoring, providing a sensitive, precise, and reproducible method suitable for clinical applications. This approach can be adapted for future CAR-T products and will support the monitoring and the management of CAR-T cell therapies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
READING GUIDES
了解这条资料涉及的技术、疾病或试验登记信息,再回到原始来源核实。
MEMBER ACCOUNT
登录成功会直接打开下一页。